Skip to main content
Have a personal or library account? Click to login
Learnings from the 2024 Utah Cardiac Recovery Symposium: A Roadmap for the Field of Myocardial Recovery Cover

Learnings from the 2024 Utah Cardiac Recovery Symposium: A Roadmap for the Field of Myocardial Recovery

Open Access
|Aug 2024

References

  1. Huggins GS, Kinnamon DD, Haas GJ, et al. Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. JAMA. 2022 Feb 1;327(5):454-463. doi: 10.1001/jama.2021.24674
  2. Felkin LE, Walsh R, Ware JS, et al. Recovery of Cardiac Function in Cardiomyopathy Caused by Titin Truncation. JAMA Cardiol. 2016 May 1;1(2):234-5. doi: 10.1001/jamacardio.2016.0208
  3. Coste Pradas J, Auguste G, Matkovich SJ, et al. Identification of Genes and Pathways Regulated by Lamin A in Heart. J Am Heart Assoc. 2020 Aug 18;9(16):e015690. doi: 10.1161/JAHA.119.015690
  4. Sadek H, Olson EN. Toward the Goal of Human Heart Regeneration. Cell Stem Cell. 2020 Jan 2;26(1):7-16. doi: 10.1016/j.stem.2019.12.004
  5. Deacon DC, Happe CL, Chen C, et al. Combinatorial interactions of genetic variants in human cardiomyopathy. Nat Biomed Eng. 2019 Feb 3;3(2):147-157. doi: 10.1038/s41551-019-0348-9
  6. Destici E, Zhu F, Tran S, et al. Human-gained heart enhancers are associated with species-specific cardiac attributes. Nat Cardiovasc Res. 2022 Sep;1(9):830-843. doi: 10.1038/s44161-022-00124-7
  7. Zhang Y, Bassel-Duby R, Olson EN. CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System. Methods Mol Biol. 2023;2587:411-425. doi: 10.1007/978-1-0716-2772-3_21
  8. Long C, Li H, Tiburcy M, et al. Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. Sci Adv. 2018 Jan 31;4(1):eaap9004. doi: 10.1126/sciadv.aap9004
  9. Zhang Y, Nishiyama T, Li H, et al. A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation. Mol Ther Methods Clin Dev. 2021 Jun 4;22:122-132. doi: 10.1016/j.omtm.2021.05.014
  10. Helgadottir A, Thorleifsson G, Snaebjarnarson A, et al. Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysis. Eur J Prev Cardiol. 2022 Dec 21:29(18):2374-2385. doi: 10.1093/eurjpc/zwac219
  11. Ghouse J, Tragante V, Ahlberg G, et al. Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism. Nat Genet. 2023 Mar;55(3):399-409. doi: 10.1038/s41588-022-01286-7
  12. Snaebjarnarson AS, Helgadottir A, Arnadottir GA, et al. Complex effects of sequence variants on lipid levels and coronary artery disease. Cell. 2023 Sep 14;186(19):4085-4099.e15. doi: 10.1016/j.cell.2023.08.01
  13. National Library of Medicine [Internet]. Washington, DC: National Library of Medicine; c2024. Lee DSM, Cardone KM, Zhang DY, et al. Common- and rare-variant genetic architecture of heart failure across the allele frequency spectrum; 2023 Oct 2 [cited 2024 Jul 10]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371173/
  14. Kolwicz SCJr., Purohit S, Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res. 2013 Aug 16;113(5):603-16. doi: 10.1161/CIRCRESAHA.113.302095
  15. Cluntun AA, Badolia R, Lettlova S, et al. The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. Cell Metab. 2021 Mar 2;33(3):629-648.e10. doi: 10.1016/j.cmet.2020.12.003
  16. Ng SM, Neubauer S, Rider OJ. Myocardial Metabolism in Heart Failure. Curr Heart Fail Rep. 2023 Feb;20(1):63-75. doi: 10.1007/s11897-023-00589-y
  17. Karwi QG, Lopaschuk GD. Branched-Chain Amino Acid Metabolism in the Failing Heart. Cardiovasc Drugs Ther. 2023 Apr;37(2):413-420. doi: 10.1007/s10557-022-07320-4
  18. Park TS, Hu Y, Noh HL, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res. 2008 Oct;49(10):2101-12. doi: 10.1194/jlr.M800147-JLR200
  19. Sasset L, Manzo OL, Zhang Y, et al. Nogo-A reduces ceramide de novo biosynthesis to protect from heart failure. Cardiovasc Res. 2023 Mar 31;119(2):506-519. doi: 10.1093/cvr/cvac108
  20. Ji R, Akashi H, Drosatos K, et al. Increased de novo ceramide synthesis and accumulation in failing myocardium. JCI Insight. 2017 May 4;2(9):e82922. doi: 10.1172/jci.insight.82922
  21. Wilkerson JL, Tatum SM, Holland WL, Summers SA. Ceramides are fuel gauges on the drive to cardiometabolic disease. Physiol Rev. 2024 Jul 1;104(3):1061-1119. doi: 10.1152/physrev.00008.2023
  22. Cantalupo A, Sasset L, Gargiulo A, et al. Endothelial Sphingolipid De Novo Synthesis Controls Blood Pressure by Regulating Signal Transduction and NO via Ceramide. Hypertension, 2020 May;75(5):1279-1288. doi: 10.1161/HYPERTENSIONAHA.119.14507
  23. McDonagh TA, Metra M, Adamo M, et al. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670
  24. Kaplon-Cieslicka A, Benson L, Chioncel O, et al.; on behalf of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2022 Feb;24(2):335-350. doi: 10.1002/ejhf.2408
  25. Tsao CW, Lyass A, Enserro D, et al. Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. JACC Heart Fail. 2018 Aug;6(8):678-685. doi: 10.1016/j.jchf.2018.03.006
  26. Florea VG, Rector TS, Anand IS, Cohn JN. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial. Circ Heart Fail. 2016 Jul;9(7):e003123. doi: 10.1161/CIRCHEARTFAILURE.116.003123
  27. Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020 Aug 11;76(6):719-734. doi: 10.1016/j.jacc.2020.05.075
  28. Heidenreich, PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063
  29. Wang G, Cruz AS, Youker K, et al. Role of Endothelial and Mesenchymal Cell Transitions in Heart Failure and Recovery Thereafter. Front Genet. 2021 Jan 15;11:609262. doi: 10.3389/fgene.2020.609262
  30. Weinheimer CJ, Kovacs A, Evans S, Matkovich SJ, Barger PM, Mann DL. Load-Dependent Changes in Left Ventricular Structure and Function in a Pathophysiologically Relevant Murine Model of Reversible Heart Failure. Circ Heart Fail. 2018 May;11(5):e004351. doi: 10.1161/CIRCHEARTFAILURE.117.004351
  31. Visker JR, Brintz BJ, Kyriakopoulos CP, et al. Integrating molecular and clinical variables to predict myocardial recovery. bioRxiv. 2024 Apr 20. doi: 10.1101/2024.04.16.589326
  32. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019 Jan 5;393(10166):61-73. doi: 10.1016/S0140-6736(18)32484-X
  33. Moon J, Ko YG, Chung N, et al. Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol. 2009 May;25(5):e147-50. doi: 10.1016/s0828-282x(09)70497-0
  34. Wilcox J, Yancy CW. Stopping medication for heart failure with improved ejection fraction. Lancet. 2019 Jan 5;393(10166):8-10. doi: 10.1016/S0140-6736(18)32825-3
  35. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563
  36. Baggio LL, Yusta B, Mulvihill EE, et al. GLP-1 Receptor Expression Within the Human Heart. Endocrinology. 2018 Apr 1;159(4):1570-1584. doi: 10.1210/en.2018-00004
  37. Khan MS, Fonarow GC, McGuire DK, et al. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation. 2020 Sep 22;142(12):1205-1218. doi: 10.1161/CIRCULATIONAHA.120.045888
  38. Triposkiadis F, Xanthopoulos A, Drakos SG, et al. Back to the basics: The need for an etiological classification of chronic heart failure. Curr Probl Cardiol. 2024 Apr;49(4):102460. doi: 10.1016/j.cpcardiol.2024.102460
  39. Frea S, Centofanti P, Pidello S, et al. Noninvasive Assessment of Hemodynamic Status in HeartWare Left Ventricular Assist Device Patients: Validation of an Echocardiographic Approach. JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 1):1121-1131. doi: 10.1016/j.jcmg.2018.01.026
  40. Vidula H, Takeda K, Estep JD, et al. Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial. JACC Heart Fail. 2022 Jul;10(7):470-481. doi: 10.1016/j.jchf.2022.03.007
  41. Tedford RJ, Leacche M, Lorts A, Drakos SG, Pagani FD, Cowger J. Durable Mechanical Circulatory Support: JACC Scientific Statement. J Am Coll Cardiol. 2023 Oct 3;82(14):1464-1481. doi: 10.1016/j.jacc.2023.07.019
  42. Grinstein J, Kruse E, Sayer G, et al. Novel echocardiographic parameters of aortic insufficiency in continuous-flow left ventricular assist devices and clinical outcome. J Heart Lung Transplant. 2016 Aug;35(8):976-85. doi: 10.1016/j.healun.2016.05.009
  43. Uriel N, Milano C, Agarwal R, et al. Incidence and clinical correlates of de-novo aortic regurgitation with a fully magnetically levitated left ventricular assist device: a MOMENTUM 3 trial portfolio analysis. Eur J Heart Fail. 2023 Feb;25(2):286-294. doi: 10.1002/ejhf.2746
  44. Topkara VK, Garan AR, Fine B, et al. Myocardial Recovery in Patients Receiving Contemporary Left Ventricular Assist Devices: Results From the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Circ Heart Fail. 2016 Jul;9(7):e003157. doi: 10.1161/CIRCHEARTFAILURE.116.003157
  45. Wever-Pinzon O, Drakos SG, McKellar SH, et al. Cardiac Recovery During Long-Term Left Ventricular Assist Device Support. J Am Coll Cardiol. 2016 Oct 4;68(14):1540-53. doi: 10.1016/j.jacc.2016.07.743
  46. Drakos SG, Pagani FD, Lundberg MS, Baldwin JT. Advancing the Science of Myocardial Recovery With Mechanical Circulatory Support: A Working Group of the National, Heart, Lung and Blood Institute. J Card Fail. 2017 May;23(5):416-421. doi: 10.1016/j.cardfail.2017.04.005
  47. Kanwar MK, Selzman CH, Ton VK, et al. Clinical myocardial recovery in advanced heart failure with long term left ventricular assist device support. J Heart Lung Transplant. 2022 Oct;41(10):1324-1334. doi: 10.1016/j.healun.2022.05.015
  48. Saeed D, Feldman D, Banayosy AE, et al. The 2023 International Society for Heart and Lung Transplantation Guidelines for Mechanical Circulatory Support: A 10-year Update. J Heart Lung Transplant. 2023 Jul;42(7):e1-e222. doi: 10.1016/j.healun.2022.12.004
  49. Nickel I, Potapov E, Sun B, et al. Deactivation of LVAD support for myocardial recovery-surgical perspectives. J Heart Lung Transplant. 2024 May 12:S1053-2498(24)01662-0. doi: 10.1016/j.healun.2024.05.005. Online ahead of print.
  50. Virani SS, Alonso A, Aparicio HJ, et al. American Heart Association Council on, E.; Prevention Statistics, C.; Stroke Statistics, S., Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950
  51. Schluep M, Gravesteijn BY. Stolker RJ. Endeman H, Hoeks SE. One-year survival after in-hospital cardiac arrest: A systematic review and meta-analysis. Resuscitation. 2018 Nov;132:90-100. doi: 10.1016/j.resuscitation.2018.09.001
  52. Thompson LE, Chan PS, Tang F, et al. American Heart Association›s Get With the Guidelines-Resuscitation, I., Long-Term Survival Trends of Medicare Patients After In-Hospital Cardiac Arrest: Insights from Get With The Guidelines-Resuscitation®. Resuscitation. 2018 Feb;123:58-64. doi: 10.1016/j.resuscitation.2017.10.023
  53. Chan PS, McNally B, Tang F, Kellermann A, Group CS. Recent trends in survival from out-of-hospital cardiac arrest in the United States. Circulation. 2014 Nov 18;130(21):1876-82. doi: 10.1161/CIRCULATIONAHA.114.009711
  54. Girotra S, Nallamothu BK, Spertus JA, Li Y, Krumholz HM, Chan PS. American Heart Association Get with the Guidelines-Resuscitation, I., Trends in survival after in-hospital cardiac arrest. N Engl J Med. 2012 Nov 15;367(20):1912-20. doi: 10.1056/NEJMoa1109148
  55. McNally B, Robb R, Mehta M, et al. Centers for Disease, C.; Prevention, Out-of-hospital cardiac arrest surveillance --- Cardiac Arrest Registry to Enhance Survival (CARES), United States, October 1, 2005--December 31, 2010. MMWR Surveill Summ. 2011 Jul 29;60(8):1-19. PMID: 21796098
  56. Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics, C.; Stroke Statistics, S., Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27;131(4):e29-322. doi: 10.1161/CIR.0000000000000152
  57. Shin TG, Jo IJ, Sim MS, et al. Two-year survival and neurological outcome of in-hospital cardiac arrest patients rescued by extracorporeal cardiopulmonary resuscitation. Int J Cardiol. 2013 Oct 9;168(4):3424-30. doi: 10.1016/j.ijcard.2013.04.183
  58. Chen YS, Yu HY, Huang SC, et al. Extracorporeal membrane oxygenation support can extend the duration of cardiopulmonary resuscitation. Crit Care Med. 2008 Sep;36(9):2529-35. doi: 10.1097/CCM.0b013e318183f491
  59. Tonna JE, McKellar SH, Selzman CH, et al. Exploratory analysis of myocardial function after extracorporeal cardiopulmonary resuscitation vs conventional cardiopulmonary resuscitation. BMC Res Notes. 2020 Mar 6;13(1):137. doi: 10.1186/s13104-020-04982-x
  60. Yannopoulos D, Bartos JA, Raveendran G, et al. Coronary Artery Disease in Patients With Out-of-Hospital Refractory Ventricular Fibrillation Cardiac Arrest. J Am Coll Cardiol. 2017 Aug 29;70(9):1109-1117. doi: 10.1016/j.jacc.2017.06.059
  61. Yannopoulos D, Bartos JA. Aufderheide TP, et al. The Evolving Role of the Cardiac Catheterization Laboratory in the Management of Patients With Out-of-Hospital Cardiac Arrest: A Scientific Statement From the American Heart Association. Circulation. 2019 Mar 19;139(12):e530-e552. doi: 10.1161/CIR.0000000000000630
  62. Lamhaut L, Tea V, Raphalen JH, et al. Coronary lesions in refractory out of hospital cardiac arrest (OHCA) treated by extra corporeal pulmonary resuscitation (ECPR). Resuscitation. 2018 May;126:154-159. doi: 10.1016/j.resuscitation.2017.12.017
  63. Diakos NA, Taleb I, Kyriakopoulos CP, et al. Circulating and Myocardial Cytokines Predict Cardiac Structural and Functional Improvement in Patients With Heart Failure Undergoing Mechanical Circulatory Support. J Am Heart Assoc. 2021 Oct 19;10(20):e020238. doi: 10.1161/JAHA.120.020238
  64. Drakos SG, Badolia R, Makaju A, et al. Distinct Transcriptomic and Proteomic Profile Specifies Patients Who Have Heart Failure With Potential of Myocardial Recovery on Mechanical Unloading and Circulatory Support. Circulation. 2023 Jan 31;147(5):409-424. doi: 10.1161/CIRCULATIONAHA.121.056600
  65. Seidel T, Navankasattusas S, Ahmad A, et al. Sheet-Like Remodeling of the Transverse Tubular System in Human Heart Failure Impairs Excitation-Contraction Coupling and Functional Recovery by Mechanical Unloading. Circulation. 2017 Apr 25;135(17):1632-1645. doi: 10.1161/CIRCULATIONAHA.116.024470
  66. Mann DL, Barger PM. Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol. 2012 Dec 18;60(24):2465-72. doi: 10.1016/j.jacc.2012.06.062
DOI: https://doi.org/10.14797/mdcvj.1443 | Journal eISSN: 1947-6108
Language: English
Page range: 88 - 97
Submitted on: Jul 3, 2024
Accepted on: Jul 4, 2024
Published on: Aug 20, 2024
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2024 Muthu Kumar Krishnamoorthi, Konstantinos Sideris, Arvind Bhimaraj, Stavros G. Drakos, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.